Why the study?
Does nicardipine improve exercise capacity and delay ischemia in patients with chronic stable effort angina pectoris?
Does nicardipine improve exercise capacity and delay ischemia in patients with chronic stable effort angina pectoris?
Nicardipine at 90 mg/day significantly improves exercise capacity and delays the onset of angina and ischemia in patients with chronic stable angina, though gradual dose titration is needed to minimize adverse effects.
Answers are grounded in this paper and cite their sources.
Supports nicardipine for symptom relief in stable angina; confirms anti-ischemic efficacy versus placebo in RCT.
The dose-related efficacy and safety of nicardipine, a new calcium antagonist of the dihydropyridine class, was assessed by exercise tolerance testing in a randomized, double-blinded, placebo-controlled study in 19 patients with chronic, stable effort angina pectoris. Four patients were assigned to each of four treatment sequences receiving nicardipine three times daily in an extended Latin-Square study design. An increase in total exercise capacity, time to onset of angina and time to 1 mm ST segment depression was observed with nicardipine 90 mg/day compared to placebo (P less than .05). Gradual upward dose titration in 30 mg/day increments starting from 30 mg/day appeared to produce maximal increase in exercise capacity. Two patients developed adverse side effects attributable to the drug when administered nicardipine 90 mg/day directly from placebo.
No takes yet. Share an insight, caveat, or question.
Thomas et al. (1990) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: